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may help clinicians make better decisions in the effort to become
victorious over SARS-CoV-2.
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To the Editor—Coronavirus disease 2019 (COVID-19) is a
respiratory tract infection ranging from mild respiratory illness
(eg, respiratory symptoms, cough, fever, shortness of breath and
breathing difficulties) to severe illness (eg, pneumonia, severe acute
respiratory syndrome, kidney failure, and death)1 that has caused an
unprecedented global crises in <90 days in all 206 countries of the
world.2 Today, most of the world’s major cities are in full quarantine
and all social and economic behaviors have been limited due to the
SARS-Cov-2 outbreak. Controlling the spread of the virus has
become one of themost important challenges for governments across
the globe. The increase inCOVID-19 cases in the advanced industrial
countries, including Italy, Germany, France, Spain, and United
States, reflects the rapid spread of the virus. As of April 4, 2020,
the following countries have been most affected: Italy, with a popu-
lations of almost 60 million, has ~119,827 COVID-19 patients
(case fatality rate [CFR], 12.25%). Germany, with a population of
almost 82 million, has ~85,778 COVID-19 patients (CFR, 1.34%).
France, with a population of almost 66 million, has ~63,536
COVID-19 patients (CFR, 10.21%). Spain, with a population of
almost 46 million, has ~117,710 patients (CFR, 9.28%). And the
United States, with a population of 320million, has ~241,703 patients
(CFR, 2.42%). The prevalence of SARS-CoV-2 is rapidly increasing.
Iran, with a population of almost 81million, has ~44,605 COVID-19
patients, with 2,898 deaths (Fig. 1). Although Iran has been heavily
sanctioned in all fields of industry and pharmacy, it has taken impor-
tant steps from the earliest days of the outbreak to combat the virus.3
For example, Italy, with an outbreak date similar to that of Iran,
has more than twice the disease incidence rate of Iran. According to
reports released by the ministries of health in Iran and Italy,4,5 Iran
formed a headquarters for the COVID-19 crisis on February 23, when
the virus count was ~15 people per day. In contrast, in Italy, the
COVID-19 crisis headquarters was formed on March 13, when the
outbreak count was ~2,500 per day. Also, these countries’ respective
healthministries published safety and prevention guidelines formany
locations, especially crowded centers including hospitals, clubs, trans-
portation systems, schools, etc, in the early days of the outbreak. They
also sought widespread collaboration with NGOs and volunteers as
well as extensive intragovernmental collaboration to ensure the obser-
vation of safety protocols to control the spread of disease. Although
traffic and concentration laws as well as heavy fines were not consid-
ered in the early days, these collaborations ultimately resulted in an
80% reduction in traffic between cities and as well as in social gather-
ings and even family gatherings. Ultimately, all of thesemeasures have
led Iran to better control the spread of the virus than other aforemen-
tioned industrialized countries.Nevertheless, Iran has a longway to go
to achieve complete control of the pandemic.
Because Iran is located among neighboring countries in a very
high-risk area for many diseases, including tuberculosis, rabies,
Crimean Congo fever, cholera, brucella, malaria, polio, and some
others, it has been even more successful in controlling such
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diseases than the United States.6 This experience and history are
expected to be very useful and effective in controlling COVID-19.
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To the Editor—The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is the virus responsible for COVID-19, which emerged
in Wuhan, China, in December 2019. The current pandemic appears
to be characterized by human-to-human transmission; it occurs
through cough, sneeze, droplet inhalation, and direct contact of
hands with mouth, nose, and eyes. The virus resides in the mucous
membranes and it is transmitted through the saliva and the
respiratory droplets. Although prevention of person-to-person
transmission is the key to limiting the pandemic, so far, little
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